Information Provided By:
Fly News Breaks for June 22, 2018
SRPT
Jun 22, 2018 | 07:34 EDT
SunTrust analyst Edward Nash raised his price target on Sarepta to $176 and kept his Buy rating after the company's R&D day where it presented preliminary results from the Phase I/IIa micro-dystrophin gene therapy program. Nash said the 3-month data "showed robust micro-dystrophin expression in muscle using Western blot and immunohistochemistry". The analyst states that he views the gene therapy program as "extremely promising", while also noting the company's other therapeutic modalities for DMD and LGMD.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.